5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancer
Samual Adams, Lindsey Phelan, Therese Lewis, Josie Behm, Aggie Law, Xianglin Shi, Guangyuan Frank Li, Jianneng Li
This paper evaluates 5β-Dihydrotestosterone (5β-DHT) as a potential alternative to testosterone in bipolar androgen therapy (BAT) for prostate cancer, showing it activates AR signaling in mutant AR contexts and suppresses tumor growth with fewer side effects.
bioRxiv · Jul 15, 2026 · PreprintCancer Biology